Recombinant vaccine plus anti-parasitic agent in an immunotherapeutic schedules induce partial regression of tegumentary leishmaniasis in a murine model
Vaccine·
- DOI
- 10.1016/j.vaccine.2026.128990
- PMID
- 42546635
- PMCID
- —
- OpenAlex
- W7172300930
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Current management options for tegumentary leishmaniasis face constraints regarding efficacy and adverse effects. This laboratory-based analysis highlights a potentially safer and more effective combinatorial approach that warrants subsequent developmental stages.
Structured evidence summary
Research question
The investigation assesses whether a combined regimen of a recombinant protein, an adjuvant, and an antiparasitic medication can effectively manage experimental leishmaniasis in a laboratory animal model.
Study design
This represents a controlled preclinical trial utilizing a murine infection model. Animals received targeted therapies and underwent parasitological, immunological, and biochemical assessments at one-month intervals following intervention.
Population and setting
The research utilized BALB/c mice experimentally challenged with Leishmania amazonensis. No human subjects or field-based clinical environments were involved in the protocol.
Main findings
The three-drug regimen demonstrated superior therapeutic outcomes compared to all other tested groups. Treated subjects displayed heightened Th1-mediated immune activation alongside marked reductions in tissue parasite counts. Standard hematological and organ function indicators remained within normal ranges throughout the observation period.
Public-health relevance
Current management options for tegumentary leishmaniasis face constraints regarding efficacy and adverse effects. This laboratory-based analysis highlights a potentially safer and more effective combinatorial approach that warrants subsequent developmental stages.
Important limitations
The experimental framework relies exclusively on a single inbred mouse strain and a defined parasite isolate. Consequently, translational applicability to human populations remains unverified within this report.
GIDS interpretation
Indexed under treatment and vaccination categories, this publication offers mechanistic data on a novel immunotherapeutic construct. Researchers monitoring combinatorial interventions for neglected parasitic diseases may find the reported immune profiling and safety metrics useful for contextual mapping.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 8 auditable classifier relationships to diseases, places, topics, and study design.